Envestnet Asset Management Inc. Acquires 3,175 Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX)

Envestnet Asset Management Inc. boosted its holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) by 54.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,982 shares of the biopharmaceutical company’s stock after acquiring an additional 3,175 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Prometheus Biosciences were worth $988,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. lifted its position in Prometheus Biosciences by 17.6% in the 3rd quarter. BlackRock Inc. now owns 2,134,272 shares of the biopharmaceutical company’s stock valued at $125,945,000 after acquiring an additional 319,310 shares in the last quarter. State Street Corp lifted its position in Prometheus Biosciences by 226.9% in the 3rd quarter. State Street Corp now owns 1,586,074 shares of the biopharmaceutical company’s stock valued at $93,594,000 after acquiring an additional 1,100,857 shares in the last quarter. Vanguard Group Inc. lifted its position in Prometheus Biosciences by 26.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,561,606 shares of the biopharmaceutical company’s stock valued at $92,151,000 after acquiring an additional 328,397 shares in the last quarter. Fred Alger Management LLC lifted its position in Prometheus Biosciences by 325.5% in the 3rd quarter. Fred Alger Management LLC now owns 1,036,165 shares of the biopharmaceutical company’s stock valued at $61,144,000 after acquiring an additional 792,620 shares in the last quarter. Finally, FMR LLC lifted its position in Prometheus Biosciences by 17.1% in the 2nd quarter. FMR LLC now owns 353,185 shares of the biopharmaceutical company’s stock valued at $9,970,000 after acquiring an additional 51,488 shares in the last quarter. 78.31% of the stock is owned by institutional investors.

Prometheus Biosciences Stock Down 0.0 %

Shares of NASDAQ RXDX opened at $198.60 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 37.56 and a quick ratio of 37.56. The company has a market cap of $9.50 billion, a P/E ratio of -56.42 and a beta of -0.50. Prometheus Biosciences, Inc. has a 1 year low of $22.31 and a 1 year high of $198.99. The firm has a 50-day simple moving average of $159.25 and a two-hundred day simple moving average of $119.34.

Prometheus Biosciences (NASDAQ:RXDX – Get Rating) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.06. The business had revenue of $1.11 million during the quarter, compared to the consensus estimate of $0.46 million. Prometheus Biosciences had a negative net margin of 3,768.76% and a negative return on equity of 33.50%. The business’s revenue was down 71.8% on a year-over-year basis. Research analysts anticipate that Prometheus Biosciences, Inc. will post -3.84 earnings per share for the current year.

Insiders Place Their Bets

In other Prometheus Biosciences news, CEO Mark C. Mckenna sold 700 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $125.26, for a total value of $87,682.00. Following the completion of the sale, the chief executive officer now owns 55,144 shares of the company’s stock, valued at $6,907,337.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Mark C. Mckenna sold 10,620 shares of Prometheus Biosciences stock in a transaction that occurred on Friday, March 3rd. The shares were sold at an average price of $125.13, for a total transaction of $1,328,880.60. Following the completion of the sale, the chief executive officer now owns 55,144 shares of the company’s stock, valued at $6,900,168.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Mark C. Mckenna sold 700 shares of Prometheus Biosciences stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $125.26, for a total transaction of $87,682.00. Following the sale, the chief executive officer now directly owns 55,144 shares of the company’s stock, valued at approximately $6,907,337.44. The disclosure for this sale can be found here. Insiders sold a total of 921,320 shares of company stock valued at $105,745,913 over the last 90 days. Insiders own 13.08% of the company’s stock.

Analyst Ratings Changes

RXDX has been the topic of several research analyst reports. The Goldman Sachs Group increased their price target on Prometheus Biosciences from $117.00 to $144.00 and gave the company a “buy” rating in a report on Tuesday, January 31st. Royal Bank of Canada lowered Prometheus Biosciences from an “outperform” rating to a “sector perform” rating in a research report on Tuesday, April 18th. Oppenheimer raised their price objective on Prometheus Biosciences from $125.00 to $150.00 and gave the company an “outperform” rating in a research report on Wednesday, March 1st. Jefferies Financial Group lowered Prometheus Biosciences from a “buy” rating to a “hold” rating and raised their price objective for the company from $160.00 to $200.00 in a research report on Wednesday, May 10th. Finally, Piper Sandler lowered Prometheus Biosciences from an “overweight” rating to a “neutral” rating in a research report on Monday, April 17th. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Prometheus Biosciences has a consensus rating of “Hold” and an average price target of $153.36.

Prometheus Biosciences Profile

(Get Rating)

Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.